John Clapham is CEO of Future Cures and PSC Biotech. Future Cures is headquartered in Southern California, a federally recognized not-for-profit by the Internal Revenue Service (IRS), committed to the realizing the full potential of stem cell technology.
John is a graduate of University of Rhode Island, with a B.S. in Chemical Engineering, 1989. He has worked for the United States Department of Defense, Lockwood Greene Engineers (formerly CPI Plants), Johnson and Johnson and Fluor Daniel prior to founding Pharmaceutical Services Corporation and Future Cures. John is a Board Member of the International Society of Pharmaceutical Engineers (ISPE) Los Angeles Chapter. He is also a member of the Parenteral Drug Association (PDA) Drug Information Association (DIA) and American Society of Quality (ASQ).